Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Baltimore, Maryland

This page shows live ClinicalTrials.gov search results for Baltimore, Maryland, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
13749
Shown on this page
12
Current sort
Recently updated
Location scope
Baltimore, MD
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Baltimore, Maryland. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 757–768 of 13,749 matching trials in Baltimore, MD.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Baltimore

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 2Phase 3 Interventional

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

NCT07010159
View directory record Official record
Conditions
Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Interventions
KPL-387, Placebo
Drug
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
18 Years to 80 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
33
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Not yet recruiting Not applicable Interventional

GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma

NCT07852975
View directory record Official record
Conditions
Recurrent Glioma (Glioblastoma Multiforme)
Interventions
Arm 1 will use Ketone supplement 80 gm daily, Arm 2 will follow Ketogenic Diet 7 days leading up to the clinically indicated surgery.
Dietary Supplement · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 111 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Recruiting Phase 3 Interventional

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
165
States / cities
Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Recruiting Phase 3 Interventional

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
78
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Recruiting No phase listed Observational

Pompe Disease Registry Protocol

NCT00231400
View directory record Official record
Conditions
Glycogen Storage Disease Type II, Pompe Disease
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2034
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

NCT03832998
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Completed Phase 3 Interventional Results available

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

NCT03859700
View directory record Official record
Conditions
Peanut Allergy
Interventions
DBV712 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
2 Years to 5 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Deliver-EE: Evaluating Effects of Meal Delivery

NCT05357261
View directory record Official record
Conditions
Healthy
Interventions
Wellness Check and Socialization, Prepared Meals
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
66 Years and older
Enrollment
2,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
14
States / cities
San Diego, California • Clearwater, Florida • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Active, not recruiting Phase 3 Interventional

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

NCT04464226
View directory record Official record
Conditions
Cancer
Interventions
Darolutamide (Nubeqa, BAY1841788)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
36
States / cities
Homewood, Alabama • Chandler, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis

NCT07823101
View directory record Official record
Conditions
IBM, Inclusion Body Myositis, Myopathy, Myositis, ALS (Amyotrophic Lateral Sclerosis), PLS
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Recruiting Phase 1Phase 2 Interventional

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

NCT06714253
View directory record Official record
Conditions
Radiation-Induced Xerostomia and Hyposalivation
Interventions
RXRG001, Placebo
Biological
Lead sponsor
RiboX Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Palo Alto, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST
Recruiting Phase 3 Interventional

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

NCT06127407
View directory record Official record
Conditions
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Interventions
Ivosidenib 500mg, Placebo
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:19 AM EST